WallStSmart

BlackRock Inc (BLK)vsBlackRock Science and Technology Trust II (BSTZ)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

BLK leads profitability with a 22.9% profit margin vs 0.0%. BSTZ trades at a lower P/E of 4.6x. BLK earns a higher WallStSmart Score of 70/100 (B-).

BLK

Strong Buy

70

out of 100

Grade: B-

Growth: 6.0Profit: 7.5Value: 7.3Quality: 4.8
Piotroski: 2/9

BSTZ

Avoid

34

out of 100

Grade: F

Growth: 4.3Profit: 4.0Value: 7.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BLKSignificantly Overvalued (-308.5%)

Margin of Safety

-308.5%

Fair Value

$240.24

Current Price

$981.35

$741.11 premium

UndervaluedFair: $240.24Overvalued
BSTZUndervalued (+26.4%)

Margin of Safety

+26.4%

Fair Value

$31.62

Current Price

$22.11

$9.51 discount

UndervaluedFair: $31.62Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BLK6 strengths · Avg: 8.7/10
Operating MarginProfitability
36.7%10/10

Strong operational efficiency at 36.7%

Market CapQuality
$151.82B9/10

Large-cap with strong market position

Profit MarginProfitability
22.9%9/10

Keeps 23 of every $100 in revenue as profit

PEG RatioValuation
0.998/10

Growing faster than its price suggests

Price/BookValuation
2.7x8/10

Reasonable price relative to book value

Revenue GrowthGrowth
23.4%8/10

Revenue surging 23.4% year-over-year

BSTZ1 strengths · Avg: 10.0/10
P/E RatioValuation
4.6x10/10

Attractively priced relative to earnings

Areas to Watch

BLK3 concerns · Avg: 3.0/10
P/E RatioValuation
27.6x4/10

Moderate valuation

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

EPS GrowthGrowth
-31.7%2/10

Earnings declined 31.7%

BSTZ4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$1.47B3/10

Smaller company, higher risk/reward

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : BLK

The strongest argument for BLK centers on Operating Margin, Market Cap, Profit Margin. Profitability is solid with margins at 22.9% and operating margin at 36.7%. Revenue growth of 23.4% demonstrates continued momentum.

Bull Case : BSTZ

The strongest argument for BSTZ centers on P/E Ratio.

Bear Case : BLK

The primary concerns for BLK are P/E Ratio, Piotroski F-Score, EPS Growth.

Bear Case : BSTZ

The primary concerns for BSTZ are Revenue Growth, EPS Growth, Market Cap.

Key Dynamics to Monitor

BLK profiles as a growth stock while BSTZ is a value play — different risk/reward profiles.

BLK is growing revenue faster at 23.4% — sustainability is the question.

BLK generates stronger free cash flow (2.2B), providing more financial flexibility.

Monitor ASSET MANAGEMENT industry trends, competitive dynamics, and regulatory changes.

Bottom Line

BLK scores higher overall (70/100 vs 34/100), backed by strong 22.9% margins and 23.4% revenue growth. BSTZ offers better value entry with a 26.4% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

BlackRock Inc

FINANCIAL SERVICES · ASSET MANAGEMENT · USA

BlackRock, Inc. is an American multinational investment management corporation based in New York City.

BlackRock Science and Technology Trust II

FINANCIAL SERVICES · ASSET MANAGEMENT · USA

BlackRock Science and Technology Trust II (BSTZ) is a strategically managed closed-end fund by BlackRock, focusing on high-growth investments within the science and technology sectors. With a keen emphasis on innovative companies that are at the forefront of technological advancements and scientific research, BSTZ aims to capitalize on the substantial growth potential in these dynamic fields. Backed by BlackRock's extensive market expertise, the trust seeks to provide attractive total returns through a combination of capital appreciation and income generation. This fund is particularly appealing to institutional investors looking to diversify their portfolios and gain exposure to long-term trends in technological innovation and healthcare developments.

Want to dig deeper into these stocks?